Bright Peak Therapeutics

Drug Discovery · Allschwil, Switzerland · Founded 2017 · Privately Held (backing)

Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. Bright Peak Therapeutics is based in Allschwil, Switzerland and was founded in 2017. It has raised $244 million across 2 recorded rounds; the latest was a $90 million Series C in Jun 2024.

PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$244.0M
Last round
Later Stage VC (Series C)
Jun 2024
Valuation — not yet established

No valuation for Bright Peak Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($244.0M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Pro
The prices on Bright Peak Therapeutics
  • ·39 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Bright Peak Therapeutics funding history

2 rounds
DateRoundRaisedPost-money
Jun 2024Later Stage VC (Series C)$90.0M▮
Jun 2021Early Stage VC (Series B)$107.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Recent activity

In the last 90 days, Bright Peak Therapeutics's record added 9 institutional fund marks (latest period Jul 2026).

How much has Bright Peak Therapeutics raised?

Bright Peak Therapeutics has raised $244 million across 2 recorded rounds since 2021. The largest was a $90 million Series C in Jun 2024.

Bright Peak Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently in Jun 2024 ($90 million sold to 21 investors).

Institutional holders and vehicles

2 SEC-registered funds reported 39 fair-value marks on Bright Peak Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

How Bright Peak Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Bright Peak Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about Bright Peak Therapeutics

How much has Bright Peak Therapeutics raised?
Bright Peak Therapeutics has raised $244.0M in total funding across 2 recorded rounds.
When did Bright Peak Therapeutics last raise?
Bright Peak Therapeutics last raised in Jun 2024 (Later Stage VC (Series C)), raising $90.0M.